<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919229</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011A2201</org_study_id>
    <secondary_id>2013-002588-24</secondary_id>
    <nct_id>NCT01919229</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)</brief_title>
  <acronym>MONALEESA-1</acronym>
  <official_title>A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label Phase II randomized pre-surgical pharmacodynamics study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized pre-surgical pharmacodynamics study will assess the biological activity of
      LEE011 plus letrozole versus single agent letrozole in primary breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to low recruitment, it was decided to terminate the study.
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cell Cycle Response Rate Per Cell Proliferation Marker Ki67</measure>
    <time_frame>Day 1, Day15</time_frame>
    <description>Cell cycle response rate is defined by proportion of patients with natural logarithm of Ki-67 levels (expressed as percentage of baseline values) of less than 1 at the time of surgery. Since the trial was prematurely terminated, no statistical analysis was done.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of the Combination</measure>
    <time_frame>Up to 30 days after the last dose</time_frame>
    <description>Occurrence, frequency and severity of adverse events (AEs), laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Baseline, Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Expression of Retinoblastoma Protein (pRB)</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (Pharmacokinetics) Parameters, Including But Not Limited to, Cmax, Tmax, AUClast for LEE011 (and Any Relevant Metabolites) and Letrozole.</measure>
    <time_frame>Days 1, 8, 14 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG Morphology</measure>
    <time_frame>Baseline, Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between PK Concentrations and ECG Changes</measure>
    <time_frame>Day 14</time_frame>
    <description>Correlation between the QTc interval change from baseline and plasma concentrations of LEE011 and/or any relevant metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Expression of Cyclin-Dependent Kinase 1 (CDK1)</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5 mg alone once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEE011 400 mg + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEE011 600mg + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011 (ribociclib)</intervention_name>
    <description>Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.</description>
    <arm_group_label>LEE011 400 mg + letrozole</arm_group_label>
    <arm_group_label>LEE011 600mg + letrozole</arm_group_label>
    <other_name>ribociclib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Letrozole was supplied in 2.5mg tablets for oral use.</description>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_label>LEE011 400 mg + letrozole</arm_group_label>
    <arm_group_label>LEE011 600mg + letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient is ≥ 18 years old at the time of informed consent, with newly diagnosed
             resectable breast cancer, who received no prior therapy for breast cancer

          -  Patient is postmenopausal. Postmenopausal status is defined either by:

               -  Prior bilateral oophorectomy

               -  Age ≥60

               -  Age &lt;60 and amenorrhea for 12 or more months and FSH (Follicle Stimulating
                  Hormone) and estradiol in the postmenopausal range.

          -  Patient has a histologically (and/or cytologically) confirmed diagnosis of
             estrogen-receptor positive and/or progesterone receptor positive breast cancer by
             local laboratory.

          -  Patient has a grade II or grade III invasive breast cancer

          -  Patient has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer
             defined as a negative in situ hybridization test or an Immunohistochemistry (IHC)
             status of 0, 1+ or 2+ (if IHC 2+, a negative in situ hybridization (respectively
             FISH/CISH/SISH) test is required) by local laboratory testing

          -  Patient has at least one breast lesion with a diameter of ≥1.0 cm by the most accurate
             imaging modality used.

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

        Exclusion Criteria:

          -  Patient has received any prior therapy for breast cancer.

          -  Patient has a concurrent malignancy or malignancy within 3 years of randomization,
             with the exception of adequately treated, basal cell skin cancer or squamous cell
             carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.

          -  Patient has active cardiac disease or a history of cardiac dysfunction including any
             of the following:

               -  History of angina pectoris, symptomatic pericarditis, or myocardial infarction
                  within 12 months prior to study entry

               -  History of documented congestive heart failure (New York Heart Association
                  functional classification III-IV)

               -  Documented cardiomyopathy

               -  Patient has a Left Ventricular Ejection Fraction (LVEF) &lt; 50% as determined by
                  Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)

               -  History of ventricular, supraventricular, nodal arrhythmias, or any other cardiac
                  arrhythmias, Long QT Syndrome or conduction abnormality in the previous 12
                  months.

               -  Family history of QTc prolongation or of unexplainable sudden death at &lt;50 years
                  of age.

               -  On screening 12 lead ECG, any of the following cardiac parameters: bradycardia
                  (heart rate &lt; 50 at rest), tachycardia (heart rate &gt; 90 at rest), PR interval &gt;
                  220 msec, QRS interval &gt;109 msec, or QTcF &gt;450 msec.

               -  Systolic blood pressure &gt;160 mmHg or &lt;90 mmHg.

          -  Patient is currently receiving any of the following medications (see

        Appendix 1 for details):

          -  That are known strong inducers or inhibitors of CYP3A4.

          -  That have a narrow therapeutic window and are predominantly metabolized through
             CYP3A4.

          -  That have a known risk to prolong the QT interval or induce Torsades de Pointes.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group SC</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles UCLA SC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital SC-9</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2013</study_first_posted>
  <results_first_submitted>September 10, 2015</results_first_submitted>
  <results_first_submitted_qc>November 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2016</results_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR-positive</keyword>
  <keyword>HER2-negative</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>LEE011</keyword>
  <keyword>Letrozole</keyword>
  <keyword>CDK</keyword>
  <keyword>CDK4</keyword>
  <keyword>CDK6</keyword>
  <keyword>CDK4/6</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pre-surgical</keyword>
  <keyword>Postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>20 patients were screened, of those 14 patients completed the Screening phase and were randomized. 6 patients discontinued during the Screening phase; 3 patients were considered screen failure and 3 patients discontinued due to patient’s decision.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Letrozole</title>
          <description>Letrozole 2.5 mg alone once daily</description>
        </group>
        <group group_id="P2">
          <title>LEE011 400mg + Letrozole</title>
          <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
        </group>
        <group group_id="P3">
          <title>LEE011 600mg + Letrozole</title>
          <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis set (FAS) comprised of all randomized patients. Patients were analyzed according to the treatment they had been assigned to during the randomization procedure.</population>
      <group_list>
        <group group_id="B1">
          <title>Letrozole</title>
          <description>Letrozole 2.5 mg alone once daily</description>
        </group>
        <group group_id="B2">
          <title>LEE011 400mg + Letrozole</title>
          <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
        </group>
        <group group_id="B3">
          <title>LEE011 600mg + Letrozole</title>
          <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="5.48"/>
                    <measurement group_id="B2" value="64.2" spread="9.91"/>
                    <measurement group_id="B3" value="70.0" spread="4.24"/>
                    <measurement group_id="B4" value="63.8" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cell Cycle Response Rate Per Cell Proliferation Marker Ki67</title>
        <description>Cell cycle response rate is defined by proportion of patients with natural logarithm of Ki-67 levels (expressed as percentage of baseline values) of less than 1 at the time of surgery. Since the trial was prematurely terminated, no statistical analysis was done.</description>
        <time_frame>Day 1, Day15</time_frame>
        <population>Since the study was terminated, no efficacy data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole 2.5 mg alone once daily</description>
          </group>
          <group group_id="O2">
            <title>LEE011 400mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
          </group>
          <group group_id="O3">
            <title>LEE011 600mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Cell Cycle Response Rate Per Cell Proliferation Marker Ki67</title>
          <description>Cell cycle response rate is defined by proportion of patients with natural logarithm of Ki-67 levels (expressed as percentage of baseline values) of less than 1 at the time of surgery. Since the trial was prematurely terminated, no statistical analysis was done.</description>
          <population>Since the study was terminated, no efficacy data was obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of the Combination</title>
        <description>Occurrence, frequency and severity of adverse events (AEs), laboratory abnormalities</description>
        <time_frame>Up to 30 days after the last dose</time_frame>
        <population>Since the study was terminated, no efficacy data was obtained, but see Adverse Events (AE) section for all AEs collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole 2.5 mg alone once daily</description>
          </group>
          <group group_id="O2">
            <title>LEE011 400mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
          </group>
          <group group_id="O3">
            <title>LEE011 600mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of the Combination</title>
          <description>Occurrence, frequency and severity of adverse events (AEs), laboratory abnormalities</description>
          <population>Since the study was terminated, no efficacy data was obtained, but see Adverse Events (AE) section for all AEs collected.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiogram (ECG) Parameters</title>
        <time_frame>Baseline, Day 14</time_frame>
        <population>Since the study was terminated, no efficacy data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole 2.5 mg alone once daily</description>
          </group>
          <group group_id="O2">
            <title>LEE011 400mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
          </group>
          <group group_id="O3">
            <title>LEE011 600mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram (ECG) Parameters</title>
          <population>Since the study was terminated, no efficacy data was obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Expression of Retinoblastoma Protein (pRB)</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Since the study was terminated, no efficacy data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole 2.5 mg alone once daily</description>
          </group>
          <group group_id="O2">
            <title>LEE011 400mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
          </group>
          <group group_id="O3">
            <title>LEE011 600mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Expression of Retinoblastoma Protein (pRB)</title>
          <population>Since the study was terminated, no efficacy data was obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK (Pharmacokinetics) Parameters, Including But Not Limited to, Cmax, Tmax, AUClast for LEE011 (and Any Relevant Metabolites) and Letrozole.</title>
        <time_frame>Days 1, 8, 14 and 15</time_frame>
        <population>Since the study was terminated, no efficacy data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole 2.5 mg alone once daily</description>
          </group>
          <group group_id="O2">
            <title>LEE011 400mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
          </group>
          <group group_id="O3">
            <title>LEE011 600mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>PK (Pharmacokinetics) Parameters, Including But Not Limited to, Cmax, Tmax, AUClast for LEE011 (and Any Relevant Metabolites) and Letrozole.</title>
          <population>Since the study was terminated, no efficacy data was obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ECG Morphology</title>
        <time_frame>Baseline, Day 14</time_frame>
        <population>Since the study was terminated, no efficacy data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole 2.5 mg alone once daily</description>
          </group>
          <group group_id="O2">
            <title>LEE011 400mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
          </group>
          <group group_id="O3">
            <title>LEE011 600mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ECG Morphology</title>
          <population>Since the study was terminated, no efficacy data was obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between PK Concentrations and ECG Changes</title>
        <description>Correlation between the QTc interval change from baseline and plasma concentrations of LEE011 and/or any relevant metabolites</description>
        <time_frame>Day 14</time_frame>
        <population>Since the study was terminated, no efficacy data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole 2.5 mg alone once daily</description>
          </group>
          <group group_id="O2">
            <title>LEE011 400mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
          </group>
          <group group_id="O3">
            <title>LEE011 600mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between PK Concentrations and ECG Changes</title>
          <description>Correlation between the QTc interval change from baseline and plasma concentrations of LEE011 and/or any relevant metabolites</description>
          <population>Since the study was terminated, no efficacy data was obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Expression of Cyclin-Dependent Kinase 1 (CDK1)</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Since the study was terminated, no efficacy data was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole 2.5 mg alone once daily</description>
          </group>
          <group group_id="O2">
            <title>LEE011 400mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
          </group>
          <group group_id="O3">
            <title>LEE011 600mg + Letrozole</title>
            <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Expression of Cyclin-Dependent Kinase 1 (CDK1)</title>
          <population>Since the study was terminated, no efficacy data was obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Letrozole2.5mgqd</title>
          <description>Letrozole 2.5 mg alone once daily</description>
        </group>
        <group group_id="E2">
          <title>LEE400mgqd+Letrozole2.5mgqd</title>
          <description>Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.</description>
        </group>
        <group group_id="E3">
          <title>LEE600mgqd+Letrozole2.5mgqd</title>
          <description>Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

